 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
new IPO for a very old company.... thread initiated to begin the usual collection of background info. Please cut and paste from the prospectus as you cruise it and find items of interest....... Thursday April 20, 10:14 am Eastern Time Company Press Release SOURCE: Packard BioScience Company Packard BioScience Raises $108 Million in Initial Public Offering of Common Stock MERIDEN, Conn., April 20 /PRNewswire/ -- Packard BioScience Company (Nasdaq: PBSC - news) today announced an initial public offering of 12,000,000 shares of its common stock at an initial public offering price of $9.00 per share. All of the shares are being offered by the Company. The shares will trade on the Nasdaq National Market under the symbol ``PBSC.' Merrill Lynch & Co., Chase H&Q, Robert W. Baird & Co., Banc of America Securities LLC, and Thomas Weisel Partners LLC are acting as the underwriters for the offering. A substantial portion of the net proceeds from the offering will be used to reduce Packard's existing indebtedness and to increase spending associated with research and development, new product development, enhancement of existing products and strategic collaborations and acquisitions. Packard BioScience Company is a leading global developer, manufacturer and marketer of instruments and related consumables and services for use in the life sciences research and nuclear industries. The Company is primarily focused on the rapidly growing areas of drug discovery, genomics and biochip analysis and is continuing to develop integrated platforms based on a wide range of technologies and instrumentation. These platforms are designed to support the industrialization of drug discovery by bringing the benefits of miniaturization, automation and ultra-high throughput analysis to these areas. Packard's experience in working in more than 60 countries with market leading customers, has allowed the Company to establish a worldwide leadership position in many of its primary product categories, with well recognized brand names and a reputation for high quality, reliable instruments. Copies of the final prospectus related to the offering may be obtained from the following: Merrill Lynch & Co., World Financial Center, North Tower, New York, New York 10281, (212) 449-1000; Chase H&Q, 230 Park Avenue, New York, New York 10169, (212) 207-1400; Robert W. Baird & Co., 777 East Wisconsin Avenue, 28th floor, Milwaukee, Wisconsin, 53202, (414) 765-3500; Banc of America Securities LLC, 9 West 57th Street, New York, New York 10019, (212) 583-8321 or; Thomas Weisel Partners LLC, 390 Park Avenue, 16th floor, New York, New York, 10022, (212) 271-3700. Contact: Michael Zebarth, Vice President, Corporate Communications and Investor Relations of Packard BioScience Company, 203-639-2340; or Miriam Weber, ext. 352 (investors) Matthew Knight, ext. 271 (media), both of Noonan-Russo Communications, Inc., 212-696-4455 SOURCE: Packard BioScience Company | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |